Your browser doesn't support javascript.
loading
Impact of COVID-19 outbreak on hospital admissions and outcome of acute coronary syndromes in a single high-volume centre in southeastern Europe.
Petrovic, M; Milovancev, A; Kovacevic, M; Miljkovic, T; Ilic, A; Stojsic-Milosavljevic, A; Golubovic, M.
Afiliação
  • Petrovic M; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
  • Milovancev A; Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia.
  • Kovacevic M; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia. aleksandra.milovancev@mf.uns.ac.rs.
  • Miljkovic T; Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia. aleksandra.milovancev@mf.uns.ac.rs.
  • Ilic A; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
  • Stojsic-Milosavljevic A; Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia.
  • Golubovic M; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Neth Heart J ; 29(4): 230-236, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33704668
BACKGROUND: As coronavirus disease 2019 (COVID-19) has reached pandemic status, authors from the most severely affected countries have reported reduced rates of hospital admissions for patients with acute coronary syndrome (ACS). AIM: The aim of the present study was to investigate the influence of the COVID-19 outbreak on hospital admissions and outcomes in ACS patients in a single high-volume centre in southeastern Europe. METHODS: This retrospective observational study aimed to investigate the number of hospital admissions for ACS, clinical findings at admission, length of hospitalisation, major complications and in-hospital mortality during the COVID-19 outbreak and to compare the data with the same parameters during an equivalent time frame in 2019. For the ST-elevated myocardial infarction (STEMI) subgroup of patients, changes in ischaemic times were analysed as well. RESULTS: There was a significant reduction of 44.3% in the number of patients admitted for ACS during the COVID-19 outbreak when compared with the same period in 2019 (151 vs 271; 95% confidence interval 38.4-50.2, p < 0.01) with a higher mortality rate (13.2% vs 7.2%, p = 0.03). In 2020, patients with non-ST-elevated myocardial infarction presented more often with acute heart failure (3.3% vs 0.7%, p = 0.04). During the COVID-19 outbreak, we observed increases in the total ischaemic time (303 ± 163.4 vs 200.8 ± 156.8 min, p < 0.05) and door-to-balloon time (69.2 ± 58.4 vs 50.5 ± 31.3 min, p < 0.01) in STEMI patients. CONCLUSIONS: These findings should increase the awareness of morbidity and mortality related to missed or delayed treatment of ACS among the public and the healthcare services.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article